Shares of Myriad Genetics plunged a day after the genetic test maker chopped its fiscal year forecast due to reimbursement delays.» Read More
What are the best plays when the market enters bear territory?
So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.
Here's how you can play healthcare with either a McCain or Obama presidency!
The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"
Options are eyeing the drug sector's Alzheimer's treatments, according to one observer.
Stocks closed lower again on Wednesday. For a time, the Dow traded below the 12,000 mark for the first time since mid-March. What's the "Word on the Street?"
On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.
Pfizer treats us for everything from high cholesterol to impotence but in an ironic twist, it’s very sick itself. What’s the prescription for getting shares of Pfizer out of triage?
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Plus, Intel drags down tech, breaking news from American Airlines and UPS and much more.
Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?
Healthcare spending is expected to nearly double to $4.3 trillion by 2017. Who’s most likely to benefit and can you trade it?
BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).
Look for pharmaceutical and biotech companies to make news this week as a UBS industry conference kicks off in New York. Also, Merrill Lynch analysts believe pricing power for prescription drugs is returning. What’s the trade?
Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.